

Trygve HolmÅ,y

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606896/publications.pdf>

Version: 2024-02-01

95
papers

2,576
citations

172207

29
h-index

243296

44
g-index

101
all docs

101
docs citations

101
times ranked

3390
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 19-22.	0.9	39
2	Skogholtâ€™s diseaseâ€™A tauopathy precipitated by iron and copper?. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 70, 126915.	1.5	1
3	Stereotyped Bâ€cell responses are linked to IgG constant region polymorphisms in multiple sclerosis. <i>European Journal of Immunology</i> , 2022, 52, 550-565.	1.6	10
4	Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. <i>JAMA Neurology</i> , 2022, 79, 307.	4.5	65
5	Clinical trials in pediatric ALS: a TRICALS feasibility study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 481-488.	1.1	3
6	Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study. <i>International Journal of Epidemiology</i> , 2022, 51, 1637-1644.	0.9	4
7	Association of adverse childhood experiences with the development of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 645-650.	0.9	4
8	Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. <i>Journal of Neurology</i> , 2021, 268, 4522-4536.	1.8	34
9	Perinatal Depression and Anxiety in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e2789-e2800.	1.5	14
10	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102801.	0.9	13
11	Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e2253-e2261.	1.5	17
12	Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 329.	1.1	9
13	Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. <i>Mechanisms of Ageing and Development</i> , 2020, 186, 111208.	2.2	31
14	CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid. <i>Frontiers in Immunology</i> , 2020, 11, 598.	2.2	8
15	Î±-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 987-993.	1.4	16
16	High BMI is associated with low ALS risk. <i>Neurology</i> , 2019, 93, e424-e432.	1.5	48
17	An Update on Vitamin D and Disease Activity in Multiple Sclerosis. <i>CNS Drugs</i> , 2019, 33, 1187-1199.	2.7	59
18	Human Cysteine Cathepsins Degrade Immunoglobulin G In Vitro in a Predictable Manner. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4843.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Randomized trial of daily high-dose vitamin D ₃ in patients with RRMS receiving subcutaneous interferon β-1a. <i>Neurology</i> , 2019, 93, e1906-e1916.	1.5	88
20	Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. <i>BMC Research Notes</i> , 2019, 12, 497.	0.6	35
21	Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019, 333, 576966.	1.1	16
22	Serum sickness following rituximab therapy in multiple sclerosis. <i>Neurology: Clinical Practice</i> , 2019, 9, 519-521.	0.8	10
23	B cell depletion in the treatment of multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 261-271.	1.4	50
24	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 172-176.	1.0	18
25	Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 303-310.	1.1	18
26	Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway. <i>Journal of Neurology</i> , 2018, 265, 1295-1302.	1.8	11
27	Severe multiple sclerosis reactivation after gonadotropin treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 38-40.	0.9	10
28	Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 75.	1.0	17
29	B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 90-95.	0.9	12
30	G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1303-1309.	1.7	2
31	Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2018, 265, 2730-2736.	1.8	6
32	Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 323, 73-77.	1.1	13
33	Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-3.	0.3	6
34	Effect of high-dose vitamin D ₃ supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 395-402.	1.4	43
35	<i>Listeria monocytogenes</i> infection associated with alemtuzumab - a case for better preventive strategies. <i>BMC Neurology</i> , 2017, 17, 65.	0.8	58
36	High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. <i>BMC Neurology</i> , 2017, 17, 67.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Sequence variations in <i>C9orf72</i> downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 256-264.	1.1	17
38	Selective intrathecal enrichment of G1m1 λ -positive B cells in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 756-761.	1.7	12
39	An update on cladribine for relapsing-remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1627-1635.	0.9	16
40	Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1018-1024.	1.4	18
41	In Silico Prediction Analysis of Idiotope-Driven T α B Cell Collaboration in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 1255.	2.2	12
42	No association of tobacco use and disease activity in multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e260.	3.1	21
43	Mortality trends of amyotrophic lateral sclerosis in Norway 1951 α 2014: an age α period α cohort study. <i>Journal of Neurology</i> , 2016, 263, 2378-2385.	1.8	14
44	Severe inflammatory disease activity 14 α months after cessation of Natalizumab in a patient with Leber α ™s optic neuropathy and multiple sclerosis α a case report. <i>BMC Neurology</i> , 2016, 16, 197.	0.8	4
45	WT1 and interferon- γ -vitamin D association in MS: a longitudinal study. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 309-312.	1.0	2
46	Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. <i>Cellular and Molecular Immunology</i> , 2016, 13, 57-64.	4.8	31
47	Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 233-235.	1.4	6
48	Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 104-111.	1.4	35
49	Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2015, 2015, 1-7.	0.4	18
50	Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1856-1864.	1.4	58
51	Vitamin D status and effect of interferon- γ 1 α treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 280, 21-28.	1.1	19
52	Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: Equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome. <i>Clinical Immunology</i> , 2015, 160, 211-225.	1.4	22
53	Body mass index influence interferon-beta treatment response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 288, 92-97.	1.1	56
54	Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2713-2721.	1.8	36

#	ARTICLE	IF	CITATIONS
55	Iron and copper in progressive demyelination – New lessons from Skogholt's disease. <i>Journal of Trace Elements in Medicine and Biology</i> , 2015, 31, 183-187.	1.5	21
56	Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 388-395.	1.4	90
57	Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 122-129.	0.4	19
58	Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 376-377.	1.7	1
59	Month of birth and risk of multiple sclerosis: confounding and adjustments. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 141-144.	1.7	26
60	Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 669-674.	1.4	30
61	Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 60-65.	1.1	25
62	Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1042-1049.	1.4	80
63	Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1833-1840.	1.4	57
64	Fat-soluble vitamins as disease modulators in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 16-23.	1.0	26
65	Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 451-457.	1.4	39
66	Experiences with using mechanical in – exsufflation in amyotrophic lateral sclerosis. <i>European Journal of Physiotherapy</i> , 2013, 15, 201-207.	0.7	10
67	Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis – Association and Prediction. <i>PLoS ONE</i> , 2013, 8, e54417.	1.1	22
68	Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity. <i>PLoS ONE</i> , 2013, 8, e75021.	1.1	32
69	Vitamin D and disease activity in multiple sclerosis before and during interferon- β treatment. <i>Neurology</i> , 2012, 79, 267-273.	1.5	113
70	Hereditary motor neuron disease in a large Norwegian family with a H46R substitution in the superoxide dismutase 1 gene. <i>Neuromuscular Disorders</i> , 2012, 22, 511-521.	0.3	10
71	Vitamin D in multiple sclerosis: implications for assessment and treatment. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1101-1112.	1.4	19
72	Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 63-69.	1.0	20

#	ARTICLE	IF	CITATIONS
73	Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis – Association and Causation. <i>Viruses</i> , 2012, 4, 3701-3730.	1.5	103
74	Pasienttilfredshet ved rehabilitering av pasienter med multipel sklerose. <i>Tidsskrift for Den Norske Lægeforening</i> , 2012, 132, 523-525.	0.2	5
75	Vitamin D in the healthy and inflamed central nervous system: access and function. <i>Journal of the Neurological Sciences</i> , 2011, 311, 37-43.	0.3	66
76	The immunological basis for treatment of stiff person syndrome. <i>Journal of Neuroimmunology</i> , 2011, 231, 55-60.	1.1	27
77	Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 87-96.	1.1	23
78	G127R: A novel SOD1 mutation associated with rapidly evolving ALS and severe pain syndrome. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 478-480.	2.3	9
79	The idiotypic connection: linking infection and multiple sclerosis. <i>Trends in Immunology</i> , 2010, 31, 56-62.	2.9	9
80	The Discovery of Oligoclonal Bands: A 50-Year Anniversary. <i>European Neurology</i> , 2009, 62, 311-315.	0.6	31
81	Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 708-712.	0.6	37
82	Idiotypic-specific CD4+ T cells induce apoptosis of human oligodendrocytes. <i>Journal of Autoimmunity</i> , 2009, 32, 125-132.	3.0	13
83	25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1280-1285.	1.4	79
84	Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update. <i>Current Molecular Medicine</i> , 2009, 9, 591-611.	0.6	7
85	Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis. <i>Medical Hypotheses</i> , 2008, 70, 66-69.	0.8	55
86	Multiple sclerosis: immunopathogenesis and controversies in defining the cause. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 271-278.	1.3	45
87	Slowly Progressing Amyotrophic Lateral Sclerosis Caused by H46R SOD1 Mutation. <i>European Neurology</i> , 2007, 58, 57-58.	0.6	9
88	Intravascular Large B-Cell Lymphoma Presenting as Cerebellar and Cerebral Infarction. <i>Archives of Neurology</i> , 2007, 64, 754.	4.9	14
89	Three Elling Solheim Poems. <i>Academic Medicine</i> , 2006, 81, 474.	0.8	0
90	A Norse Contribution to the History of Neurological Diseases. <i>European Neurology</i> , 2006, 55, 57-58.	0.6	5

#	ARTICLE	IF	CITATIONS
91	ALS: Cytokine profile in cerebrospinal fluid T cell clones. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 183-186.	2.3	15
92	Infectious causes of multiple sclerosis. Lancet Neurology, The, 2005, 4, 268.	4.9	5
93	Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. European Journal of Immunology, 2005, 35, 1786-1794.	1.6	20
94	Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells. Journal of NeuroVirology, 2004, 10, 52-56.	1.0	61
95	Cerebrospinal fluid CD4+T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. Journal of NeuroVirology, 2004, 10, 278-283.	1.0	70